ImmuPharma plc (IMM.L)
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Company Info
Highlights
£18.92M
-£0.01
-£18.84K
-£745.39K
£0.82 - £7.40
£5.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in ImmuPharma plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
ImmuPharma plc had a return of 232.78% year-to-date (YTD) and 227.35% in the last 12 months. Over the past 10 years, ImmuPharma plc had an annualized return of -22.79%, while the S&P 500 had an annualized return of 11.30%, indicating that ImmuPharma plc did not perform as well as the benchmark.
IMM.L
232.78%
38.28%
130.13%
227.35%
-22.65%
-22.79%
^GSPC (Benchmark)
3.96%
2.77%
10.09%
21.57%
12.62%
11.30%
Monthly Returns
The table below presents the monthly returns of IMM.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 331.54% | 232.78% | |||||||||||
| 2024 | -19.79% | -19.25% | 96.76% | -0.00% | 0.94% | -3.03% | -9.86% | -21.60% | 23.47% | -12.40% | -25.47% | 1.69% | -27.74% |
| 2023 | 48.10% | -13.76% | -8.19% | 41.60% | -0.33% | -23.32% | -1.50% | -12.61% | -6.72% | -9.33% | 1.91% | -3.75% | -9.37% |
| 2022 | 12.03% | -26.85% | 5.50% | 10.43% | -10.24% | -1.40% | 12.28% | -1.27% | -51.04% | 24.59% | -39.21% | -20.35% | -72.33% |
| 2021 | -13.30% | -22.94% | -0.22% | 2.70% | -7.00% | 5.88% | -9.44% | -4.17% | -0.90% | -11.76% | -20.94% | 23.15% | -50.19% |
| 2020 | -7.81% | -11.19% | -23.66% | 35.50% | 18.82% | -19.88% | 6.01% | 17.92% | -28.84% | -11.11% | 31.86% | -0.74% | -16.56% |
| 2019 | -2.13% | 6.52% | -5.51% | -13.13% | 14.87% | -4.85% | -12.19% | 1.40% | -0.92% | -11.81% | 145.61% | -23.81% | 36.17% |
| 2018 | -24.41% | -5.84% | 31.40% | -81.32% | -11.45% | -8.75% | -14.58% | -2.93% | -36.18% | -13.78% | 23.74% | -13.28% | -93.09% |
| 2017 | 3.85% | 9.72% | -12.24% | 5.05% | 0.23% | -2.28% | 1.40% | -0.23% | 11.09% | 58.00% | 30.00% | 37.65% | 226.92% |
| 2016 | -5.83% | -14.16% | 7.73% | 15.31% | 7.05% | 6.20% | 10.58% | -2.97% | 0.68% | 2.03% | 1.99% | 35.06% | 73.33% |
| 2015 | 2.94% | -5.24% | -7.54% | 7.61% | -2.02% | -5.15% | -5.43% | -5.75% | -3.66% | -34.18% | -12.50% | 31.87% | -41.18% |
| 2014 | -6.75% | -1.28% | -10.34% | 6.73% | -13.51% | 11.46% | -8.41% | -8.16% | 5.56% | 38.95% | -10.61% | -13.56% | -19.05% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 89, IMM.L is among the top 11% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for ImmuPharma plc (IMM.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
ImmuPharma plc provided a 0.00% dividend yield over the last twelve months, with an annual payout of £0.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Dividend | £0.00 | £0.00 | £0.00 | £0.00 | £0.03 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 45.11% |
Monthly Dividends
The table displays the monthly dividend distributions for ImmuPharma plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | £0.00 | £0.00 | £0.00 | ||||||||||
| 2024 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 |
| 2023 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 |
| 2022 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 |
| 2021 | £0.03 | £0.03 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the ImmuPharma plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ImmuPharma plc was 99.55%, occurring on Mar 4, 2024. The portfolio has not yet recovered.
The current ImmuPharma plc drawdown is 97.89%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.55% | Jan 4, 2018 | 1556 | Mar 4, 2024 | — | — | — |
| -85.29% | Nov 19, 2009 | 1507 | Dec 4, 2015 | 509 | Dec 8, 2017 | 2016 |
| -56.82% | Jan 18, 2007 | 357 | Nov 21, 2008 | 131 | Jun 8, 2009 | 488 |
| -41.56% | May 12, 2006 | 62 | Sep 22, 2006 | 51 | Jan 2, 2007 | 113 |
| -19.83% | Jul 23, 2009 | 57 | Oct 12, 2009 | 4 | Oct 16, 2009 | 61 |
Volatility
Volatility Chart
The current ImmuPharma plc volatility is 61.98%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for ImmuPharma plc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |